Early clinical complications after ABO-incompatible live-donor kidney transplantation: A national study of medicare-insured recipients

Transplantation

Volumn 98, Issue 1, 2014, Pages 54-65

  Lentine, Krista L ^a   Axelrod, David ^b   Klein, Christina ^c   Simpkins, Christopher ^b   Xiao, Huiling ^a   Schnitzler, Mark A ^a   Tuttle Newhall, Janet E ^a   Dharnidharka, Vikas R ^c   Brennan, Daniel C ^c   Segev, Dorry L ^d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood group incompatibility; Hemorrhage; Infection; Kidney transplantation; Living donors; Medicare

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; APHERESIS; ARTICLE; BACTEREMIA; BLEEDING; BLOOD GROUP ABO INCOMPATIBILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GRAFT RECIPIENT; HOSPITAL INFECTION; HUMAN; IMMUNOADSORPTION; INCIDENCE; INFECTIOUS COMPLICATION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MEDICARE; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PYELONEPHRITIS; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SPLENECTOMY; URINARY TRACT INFECTION; WOUND INFECTION;

ABO BLOOD-GROUP SYSTEM; ADULT; BLOOD GROUP INCOMPATIBILITY; FEMALE; HISTOCOMPATIBILITY; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MEDICARE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE HEMORRHAGE; PROPORTIONAL HAZARDS MODELS; PYELONEPHRITIS; REGISTRIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; URINARY TRACT INFECTIONS;

EID: 84903738969     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000029     Document Type: Article

References (39)

1. Segev DL, Gentry SE, Melancon JK, et al. Characterization of waiting times in a simulation of kidney paired donation. Am J Transplant 2005; 5: 2448.
2. Gentry SE, Montgomery RA, Segev DL. Kidney paired donation: fundamentals, limitations, and expansions. Am J Kidney Dis 2011; 57: 144.
3. Montgomery JR, Berger JC, Warren DS, et al. Outcomes of ABOincompatible kidney transplantation in the United States. Transplantation 2012; 93: 603.
4. GaronzikWang JM,Montgomery RA, Kucirka LM, et al. Incompatible live-donor kidney transplantation in the United States: results of a national survey. Clin J Am Soc Nephrol 2011; 6: 2041.
5. Segev DL, Simpkins CE, Warren DS, et al. ABO incompatible hightiter renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005; 5: 2570.
6. OPTN (Organ Procurement and Transplantation Network)/UNOS (United Network for Organ Sharing). National Data Reports, Graft Survival by Donor Type, Latest Data. Available at: http://optn.transplant. hrsa.gov/latestData/rptStrat.asp. Accessed September 10, 2013.
7. Locke JE, Zachary AA, Haas M, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7: 842.
8. Flint SM, Walker RG, Hogan C, et al. Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression. Am J Transplant 2011; 11: 1016.
9. Genberg H, Kumlien G, Wennberg L, et al. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008; 85: 1745.
10. Habicht A, Broker V, Blume C, et al. Increase of infectious complications in ABO-incompatible kidney transplant recipientsVa single centre experience. Nephrol Dial Transplant 2011; 26: 4124.
11. Hwang JK, Kim SI, Choi BS, et al. Short-term results of ABOincompatible living donor kidney transplantation: comparison with ABO-compatible grafts. J Korean Surg Soc 2011; 81: 10.
12. Morath C, Becker LE, Leo A, et al. ABO-incompatible kidney transplantation enabled by nonYantigen-specific immunoadsorption. Transplantation 2012; 93: 827.
13. Renner FC, Czekalinska B, Kemkes-Matthes B, et al. Postoperative bleeding after AB0-incompatible living donor kidney transplantation. Transplant Proc 2010; 42: 4164.
14. Schaefer B, Tonshoff B, Schmidt J, et al. Bleeding complications in pediatric ABO-incompatible kidney transplantation. Pediatr Nephrol 2013; 28: 327.
15. Schwartz J, StegallMD, Kremers WK, Gloor J. Complications, resource utilization, and cost of ABO-incompatible living donor kidney transplantation. Transplantation 2006; 82: 155.
16. Wilpert J, Fischer KG, Pisarski P, et al. Long-term outcome of ABOincompatible living donor kidney transplantation based on antigenspecific desensitization. An observational comparative analysis. Nephrol Dial Transplant 2010; 25: 3778.
17. Kaplan A. Complications of apheresis. Semin Dial 2012; 25: 152.
18. Moriya Y, Yamaji K, Kanai Y, et al. The effectiveness of intravenous human immunoglobulin treatment after plasmapheresis in restoring serum immunoglobulin levels: a preliminary study. Ther Apher 2002; 6: 154.
19. Biglarnia AR, Nilsson B, Nilsson Ekdahl K, et al. Desensitization with antigen-specific immunoadsorption interferes with complement in ABO-incompatible kidney transplantation. Transplantation 2012; 93: 87.
20. Lee G, Arepally GM. Anticoagulation techniques in apheresis: from heparin to citrate and beyond. J Clin Apher 2012; 27: 117.
21. Chirnside A, Urbaniak SJ, Prowse CV, et al. Coagulation abnormalities following intensive plasma exchange on the cell separator. II. Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III. Br J Haematol 1981; 48: 627.
22. Hanafusa N, Hamasaki Y, Kawarasaki H, et al. The effect of different apheresis modalities on coagulation factor XIII level during antibody removal in ABO-blood type incompatible living related renal transplantation. Transfus Apher Sci 2013.
23. Yeh JH, Chiu HC. Coagulation abnormalities in serial doublefiltration plasmapheresis. J Clin Apher 2001; 16: 139.
24. Lentine KL, Rocca Rey LA, Kolli S, et al. Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure. Clin J Am Soc Nephrol 2008; 3: 1090.
25. Kutinova A, Woodward RS, Ricci JF, et al. The incidence and costs of sepsis and pneumonia before and after renal transplantation in the United States. Am J Transplant 2006; 6: 129.
26. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
27. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16: 496.
28. Alexandre GP, Squifflet JP, De Bruyere M, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987; 19: 4538.
29. Alexandre GP, De Bruyere M, Squifflet JP, et al. Human ABOincompatible living donor renal homografts. Neth J Med 1985; 28: 231.
30. Tyden G, Kumlien G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145.
31. Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003; 76: 730.
32. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315.
33. Whiting JF, Woodward RS, Zavala EY, et al. Economic cost of expanded criteria donors in cadaveric renal transplantation: analysis of Medicare payments. Transplantation 2000; 70: 755.
34. Redfield RR, Parsons RF, Rodriguez E, et al. Underutilization of A2 ABO incompatible kidney transplantation. Clin Transplant 2012; 26: 489.
35. Gloor JM, Stegall MD. ABO incompatible kidney transplantation. Curr Opin Nephrol Hypertens 2007; 16: 529.
36. Lentine KL, Gheorghian A, Axelrod D, et al. The implications of acute rejection for allograft survival in contemporary U.S. kidney transplantation. Transplantation 2012; 94: 369.
37. Gheorghian A, Schnitzler MA, Axelrod DA, et al. The implications of acute rejection and reduced allograft function on health care expenditures in contemporary US kidney transplantation. Transplantation 2012; 94: 241.
38. Schnitzler MA, Gheorghian A, Axelrod D, et al. The cost implications of first anniversary renal function after living, standard criteria deceased and expanded criteria deceased donor kidney transplantation. J Med Econ 2013; 16: 75.
39. Schnitzler MA, Lentine KL, Gheorghian A, et al. Renal function following living, standard criteria deceased and expanded criteria deceased donor kidney transplantation: impact on graft failure and death. Transpl Int 2012; 25: 179.